ArticleBMC psychiatry2026
Barriers to long-acting injectable antipsychotic use for community-dwelling patients with schizophrenia in China: a qualitative process analysis.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLong-acting injectable antipsychotics (LAIs) have proven more effective for treating patients with schizophrenia than oral formulations. However, the use of LAIs in China remains low and this phenomenon is still under-researched. This study endeavors to provide a better understanding by systematically amalgamating the difficulties and barriers encountered by patients with schizophrenia in China when accessing LAIs from a process-oriented perspective, thereby making a significant contribution to filling the critical void in the existing literature.
methodsSchizophrenia patients receiving rehabilitation services at community mental health rehabilitation centres in Guangzhou, China, were sampled using a convenience sampling method. Semi-structured qualitative interviews were conducted to explore participants' attitudes and experiences with LAIs treatment, and data were coded and analysed using thematic analysis.
resultsBetween December 18, 2023, and April 23, 2024, 88 participants were recruited, including 33 patients, 33 primary caregivers, 11 community psychiatric management physicians (CPMPs), and 11 psychiatrists. Four major themes emerged from the study: (1) poorly coordinated organisational structures; (2) negative perceptions of patients regarding LAIs; (3) cautious and concern-ridden enrolment decisions; (4) unclear medication side effects. Serving as the foundation of the entire process, the poorly coordinated organisational structures described in Theme 1 provide the context for subsequent themes, which further identify specific process barriers that complicate access to LAIs.
conclusionsThis study explores barriers to LAIs treatment for schizophrenia from a process-oriented perspective, incorporating stakeholder attitudes and providing empirical evidence for clinical practice and policy improvement. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.